Bulletin
Investor Alert

Illumina Inc.

NAS: ILMN

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Feb 3, 2023, 7:59 p.m.

/zigman2/quotes/203509482/composite

$

215.00

Change

+0.74 +0.35%

Volume

Volume 55,731

Quotes are delayed by 20 min

/zigman2/quotes/203509482/composite

Previous close

$ 224.94

$ 214.26

Change

-10.68 -4.75%

Day low

Day high

$213.18

$221.24

Open

52 week low

52 week high

$173.45

$371.16

Open

Scott Gottlieb

Dr. Scott Gottlieb is a Special Partner on the NEA healthcare investment team; he was Venture Partner at NEA from in 2007 to 2017 until being appointed the 23rd Commissioner of the U.S. Food and Drug Administration (FDA), where he served from 2017 to 2019. Dr. Gottlieb’s work focuses on advancing public health through developing and implementing innovative approaches to improving medical outcomes, reshaping healthcare delivery, and expanding consumer choice and safety.

In addition to his role as an investor, Dr. Gottlieb is a physician, policy expert, and advocate for healthcare entrepreneurship, innovation, and access. Dr. Gottlieb is an elected member of the National Academy of Medicine and currently a Resident Fellow at the American Enterprise Institute (AEI) in Washington, DC. In addition to his recent role as FDA Commissioner, Dr. Gottlieb previously served as the FDA’s Deputy Commissioner for Medical and Scientific Affairs and before that, as a Senior Adviser to the Administrator of the Centers for Medicare and Medicaid Services.

Dr. Gottlieb was a practicing hospitalist and a Clinical Assistant Professor at the New York University School of Medicine. Earlier in his career, he worked as a healthcare analyst for the investment bank Alex. Brown & Sons. He completed a residency in internal medicine at the Mount Sinai Medical Center in New York and is a graduate of the Mount Sinai School of Medicine and of Wesleyan University, in Middletown, Connecticut, where he studied Economics.

In 2018 and again in 2019 Dr. Gottlieb was recognized by Fortune as one of \

Transactions

Date Shares Transaction Value
05/26/2022 1,232   Award at $0 per share. 0
05/26/2021 881   Award at $0 per share. 0
05/27/2020 963   Award at $0 per share. 0
02/04/2020 395   Award at $0 per share. 0

Officers and Executives

Mr. Francis A. deSouza
President, Chief Executive Officer & Director
Mr. Kevin Pegels
Chief-Global Operations
Dr. Joydeep Goswami
Chief Financial & Strategy Officer
Dr. Alex Aravanis
CTO, Head-Research & Product Development
Ms. Carissa Rollins
Chief Information Officer
Dr. Phillip G. Febbo
Chief Medical Officer
Ms. Susan H. Tousi
Chief Commercial Officer
Dr. Craig Michael Ciesla
Vice President
Dr. Bryan Crane
Vice President & Head-System Design
Mr. Charles E. Dadswell
Secretary & General Counsel
Ms. Paula Lynn Dowdy
SVP & GM-Commercial Operations, Europe
Ms. Kathryne Reeves
Chief Marketing Officer
Mr. Scott Ericksen
Ms. Sallilyn Schwartz
Vice President-Investor Relations
Ms. Aimee Hoyt
Chief People Officer & Senior Vice President
Mr. John Frank
Chief Public Affairs Officer
Dr. John Wendell Thompson
Chairman
Dr. Scott Gottlieb
Independent Director
Dr. Robert S. Epstein
Independent Director
Dr. Frances Hamilton Arnold
Independent Director
Mr. Philip W. Schiller
Independent Director
Ms. Caroline D. Dorsa
Independent Director
Dr. Gary S. Guthart
Independent Director
Ms. Susan E. Siegel
Independent Director
Link to MarketWatch's Slice.